Radioactive beads aim to shrink inoperable liver tumors
NCT ID NCT07391839
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a single injection of MDN-001, which contains tiny radioactive beads (Yttrium-90), in 40 people with liver cancer that cannot be removed by surgery. The goal is to see if the treatment is safe and can shrink tumors, slow disease progression, and improve quality of life. Participants will be monitored for side effects and tumor response for at least 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Yttrium-90 microspheres (radioactive beads delivered via injection)
- What this could lead to
- If successful, this could provide a new treatment option to shrink liver tumors in patients who cannot have surgery, potentially extending survival.
- What could go wrong
- This is an early phase 1/2 trial with only 40 participants, so safety and effectiveness are not yet proven. Radioactive microspheres can cause side effects like liver damage or radiation sickness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, Anhui, 230001, China
-
Henan Cancer Hospital
RECRUITINGHenan, Zhengzhou, 450008, China
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
-
The First Affiliated Hospital of Fujian Medical University
RECRUITINGFuzhou, Fujian, 350005, China
-
The First Affiliated Hospital of Jinan University
RECRUITINGGuangzhou, Guangdong, 510630, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
-
Zhongda Hospital
RECRUITINGNanjing, Jiangsu, 210009, China
-
Zhongshan hospital
RECRUITINGShanghai, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Freeze-and-Heat attack: could a new device boost liver cancer treatment?
- Liver cancer trial tests combo therapy against single drug
- AI scans 3000 liver cancer patients to pick best therapy
- New trial matches liver cancer treatment to Tumor's Fat-Burning signature
- New combo therapy shows promise for Tough-to-Treat liver cancer